THE DISTILLED 3: Top Plays for the Week of August 17, 2026

Educational content only — not financial advice, and not a recommendation to buy or sell anything (just outlining possible expressions). Options can expire worthless (100% loss of premium), and some strategies risk more than you put in; read the OCC options-risk disclosure before trading. Biotech catalyst plays are extremely volatile — stocks can gap, halt, and crater on a single readout, and post-event IV crush can sink an options position even when you’re right on direction. Catalyst dates slip. Do your own diligence and risk only what you can afford to lose.

Last week’s list lost two picks to the tape. Tenax’s LEVEL trial failed Monday — 3.5 meters on the six-minute walk, p=0.63, a 90% single-session drawdown. Definium’s Voyage hit Wednesday at p<0.0001, and the stock finished the week down. One coin flip landed tails; the other landed heads and paid nothing. That is why the Edge sections matter more than the dates.

Three names: two hard PDUFA dates and one readout that could print any morning.

#1: ZYME — Zymeworks Inc.

The Setup. August 25 PDUFA for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, filed by partner Jazz under Priority Review. Approval triggers a $250 million milestone — roughly 14% of market cap arriving as one wire transfer, with up to $190 million of further global milestones behind it. Six trading days out.

The Play. Consider stock in the mid-$20s, or selling out-of-the-money puts into the 25th to harvest elevated premium and set a lower entry — the structure flagged July 8. An approval this well-telegraphed has a long history of behaving like a buy-the-rumor event, so the run into the date may matter more than the print. Consider trimming into approval, keeping a stub for the Q3 interim survival analysis.

The Edge. The market treats this as a partner story it doesn’t have to follow. But the approval case is about as de-risked as a PDUFA gets: a positive randomized Phase 3 in NEJM (median PFS 12.4 vs 8.1 months), an existing accelerated approval in biliary tract cancer, Breakthrough Therapy Designation, Priority Review, and a real-time oncology review submission. The moat is deepest where it’s proven — composition and manufacturing claims to 2034, methods-of-use to 2042, a patent term extension filed January 2025, and twelve years of BPCIA exclusivity beneath it.

The second tell, from my August 6 note: at ~$25 the stock still trades below the $25.85 average price management itself paid under its own 2026 buyback, with $75.6 million of authorization live. A repurchase program underwater ten days before the company’s largest catalyst is a standing bid. And short interest is only ~6% of float — the move on approval isn’t a squeeze, it’s a re-rate.

The Risk. Management removed the “beyond 2028” runway sentence this quarter rather than defending it. The 10-Q now says only “at least the next twelve months,” and the company no longer intends to provide runway guidance at all. Operating burn was $77.7 million in the first half against $7.0 million of revenue. A CRL lands on a company that just stopped discussing runway, with a Royalty Pharma obligation compounding at 10.7% toward ~$481 million by 2042.

Conviction Level: High on the regulatory case. House rating stays Speculative Buy — the balance-sheet engineering underneath isn’t for everyone.

#2: RARE — Ultragenyx Pharmaceutical

The Setup. PDUFA August 23 for DTX401, an AAV8 gene therapy for glycogen storage disease type Ia — Priority Review and, critically, no Advisory Committee. The 23rd is a Sunday, so action realistically lands Friday the 21st or the following week. Three weeks later comes the September 19 UX111 PDUFA in Sanfilippo A, then Aspire topline for GTX-102 in Angelman, guided September or October. Three binaries in eight weeks, at a stock that has moved 6% in a fortnight.

The Play. Consider stock, or a defined-risk September structure. This is the cleanest entry on the board — almost none of it is priced. Consider takinggains into the first approval rather than trailing: a clean August 23 reprices both the September 19 decision and the Angelman readout, because it is the same facility and the same inspectors.

The Edge. The alpha is an 8-K nobody read. On August 11 Ultragenyx quietly disclosed a settlement, dated August 7, in the Dojolvi patent litigation: Esjay Pharma takes a royalty-free license to launch its generic beginning January 1, 2033. Against the December 2027 30-month stay everyone had penciled in as the exposure point, that is roughly six and a half additional years of protected life on a $95–100 million line at orphan-drug margin — about 13% of the top line, and arguably the most profitable 13%. It defuses one of the three explicit SELL triggers from our original deep dive. The market prices Bedford, not New Jersey.

Two more things underweighted: the FDA explicitly waived an AdCom on DTX401 — real de-risking for a novel gene therapy, where a public panel can shred vector durability and endpoint meaningfulness — and DTX301, using the same AAV8 vector in OTC deficiency, hit its Phase 3 co-primaries in March at 64% response versus 0% placebo. The platform has cross-validated itself.

The Risk. The factory is the boss, and I have called manufacturing risk CODE RED since February. Bedford drew the original CRL on UX111, and Ultragenyx is suing its own former CDMO, Catalent, for more than $100 million over alleged manufacturing failures. Both BLAs touch Bedford, so a CMC-driven CRL on the 23rd likely drags September 19 with it. The offsetting comfort: Q2 burn halved to $97 million, cash is $436 million, and runway extends into mid-2027 before counting two Priority Review Vouchers worth ~$100 million each.

Conviction Level: Medium. The clinical case is de-risked; the factory is not.

Share

Subscribe now

#3: EYPT — EyePoint Pharmaceuticals (STILL?!)

The Setup. Phase 3 LUGANO topline for DURAVYU in wet AMD, described by CEO Jay Duker on August 5 as “expected this month” — and management then cancelled its own earnings call in light of the readout. Roughly 400 patients against on-label aflibercept; primary endpoint is non-inferiority on visual acuity at a blended Week 52/56, margin −4.5 letters. With LUCIA pushed to Q4, this one dataset carries the whole program for a quarter.

The Play. Here I change posture, not rating. Last week I called an entry at $12–13; the stock is near $14.75 after a 9.4% Friday on no news, and that margin of safety is gone. Consider holding what you have; think twice before chasing. For anyone initiating, a September/October call spread could be a defensible structure. Expect a two-step reaction: topline in August, but the curves that decide the commercial story don’t show until Retina Society in September.

The Edge. Two design changes almost nobody is modeling. LUGANO and LUCIA enrolled 75% treatment-naïve patients versus DAVIO 2’s 100% previously-treated population, and cut supplemental-injection criteria from five triggers — including open investigator discretion — down to two objective ones. Treatment-naïve eyes are easier to control; tighter rescue criteria mean fewer supplemental injections propping up the control arm. Both cut in DURAVYU’s favor, on top of roughly four letters of cushion (DAVIO 2 posted −0.3 and −0.4 letter deltas against a −4.5 margin) at 90% power.

The IP also runs deeper than credited. The licensed Equinox compound patent expires September 2037, but EyePoint holds a granted U.S. patent on the DURAVYU formulation to 2043, with injector applications reaching 2046 — the patent life that makes this an M&A asset against the anti-VEGF biosimilar cliff.

The Risk. The July 2024 Warning Letter on Watertown remains unremediated — no closeout letter, corrective-action language still in the 10-Q. That is how this thesis dies on good data. There is also a mechanical failure mode: DAVIO 2 measured one dose, LUGANO measures two, and if elution from the second insert is less consistent, the blended Week 52/56 average is where it shows. Carry the corrected balance sheet — 86.2M shares, $180.5M cash, ~$94M quarterly burn.

Conviction Level: High on the thesis — BUY maintained, three consecutive DSMC continuations across 1,400+ patients, ~27% of float short. It ranks third because conviction and trade quality are not the same thing: at $14.75 the entry is the weakest part of a strong setup.

HONORABLE MENTIONS

BEAM — Beam Therapeutics. The best raw setup on the board — a dated ERS late-breaker September 8 with an investor call the same morning, stock below both moving averages, 26.6% of float short. But it has been WATCH LIST since April for one reason, and September 8 is a referendum on exactly that reason: Grade 4 ALT and Grade 3 AST after the second 60mg dose in the three-patient multi-dose cohort. Worth watching that the pivotal cohort runs at single-dose 60mg — Beam designed around the multi-dose problem rather than through it, and a clean single-dose profile at larger n would de-risk all three liver programs at once.

IRD — Opus Genetics. Speculative Buy, sized small, and it stays there. The BEST1 IP gap is disqualifying at the top of an IP-first ranking: the composition-of-matter family is still pending, not granted, on the largest population in the portfolio — roughly 22,000 patients globally — with only methods-of-use to 2041–2042 and orphan exclusivity as backstop. The dataset is five open-label patients at three months, and the sentinel’s +12 ETDRS letters came off a counting-fingers floor; Cohort 1’s three BVMD patients start with better vision and less room to move, so read the OCT first, not the acuity. Three executive 10b5-1 plans totaling up to 1.82 million shares also switch on between August 10 and September 4, delivering supply into the print.

CAPR (Capricor) — Aug 22 PDUFA, but treat the date as dead. The July 29 AdCom voted 3–9 against, and on Aug 13 management said FDA “has indicated it is willing to... extend the PDUFA action date accordingly” upon receiving a BLA amendment. Stock +73% in two weeks off the crash low on 35% short float. That’s a squeeze, not a setup.

AMLX (Amylyx) — LUCIDITY topline “late August or early September,” reaffirmed Aug 6. Real binary, but a soft window and the stock is +79% YTD.

DFTX (Definium) — Panorama Phase 3 in GAD confirmed for September, with a 50µg active-control arm. Voyage just hit and the stock is down two weeks later. Worth watching, but the catalyst it just spent was the near one.

KOD (Kodiak) — DAYBREAK Phase 3 one-year primary, “September 2026.” 26.6% of float short, 11.7 days to cover, flat two weeks. Timing may fall outside the window.

This post is educational content, not financial advice, and nothing here is a recommendation to buy or sell any security. Catalyst dates and prices move — confirm everything against primary sources, and do your own diligence before acting.